中文
About Us
Corporate Overview
Management Team
Board of Directors
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipline
Overview
HCV
HBV
ASC09
ASC06
Partnership
Investors
Financials & Filing
News
2020
2019
2018
2017
2016
2015
2014
Careers
2020
2019
2018
2017
2016
2015
2014
Ascletis to Present at the 17th Annual Morgan Stanley Asia Pacific Summit
2019-11-26
Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer
2018-11-12
Ascletis to Present Phase II / III Clinical Study for Its Innovative All-oral HCV Treatment at the 69th Annual meeting of AASLD
2018-11-06
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA
2018-10-18
Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients
2018-10-15
1
2
3
»
